Acromegaly Treatment Market to Grow with a CAGR of 6.92% through 2031F
Early diagnosis and screening programs are expected to drive growth in the global acromegaly treatment market over the forecast period,
2027-2031.
According to TechSci Research's report, “Acromegaly Treatment Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F,” the Global Acromegaly Treatment Market will grow from USD 1.72 Billion in 2025 to USD 2.57 Billion by 2031 at a 6.92% CAGR.
The Global Acromegaly Treatment Market has witnessed
significant growth in recent years, driven by various factors that are
reshaping the landscape of acromegaly management. Acromegaly is a rare
endocrine disorder characterized by the excessive secretion of growth hormone
(GH) in adults, primarily caused by benign tumors in the pituitary gland. This
condition leads to abnormal growth of bones and tissues and is associated with
various health complications. One of the primary drivers of growth in the acromegaly treatment market is the ongoing development of innovative
therapeutic approaches. Traditionally, treatment options for acromegaly
included surgery and radiation therapy to remove or shrink the pituitary tumor
responsible for GH overproduction.
However, advances in pharmaceuticals have
led to the introduction of novel medical therapies. These include somatostatin
analogs, growth hormone receptor antagonists, and dopamine agonists, which provide patients with a wider range of options for managing their condition
effectively. The availability of these newer treatments has not only improved
patient outcomes but also significantly expanded the market. Another
driving force behind the growth of the global acromegaly treatment market is
the increasing incidence of this rare disorder. While acromegaly remains a
relatively uncommon condition, advances in diagnostic techniques have facilitated earlier detection. As healthcare professionals and patients become more
aware of the symptoms and signs of acromegaly, the number of diagnosed cases
has risen. Early diagnosis enables timely intervention and improved disease management, making treatment a crucial component of acromegaly care. The
growing number of patients seeking treatment has contributed to the market's
expansion.
The growth of the global acromegaly treatment market is
further bolstered by the development of healthcare infrastructure in emerging
economies. As these nations invest in healthcare systems and facilities, there
is an increased emphasis on diagnosing and treating rare diseases like
acromegaly. Improved access to healthcare services and specialized treatment
centers ensure that patients have better opportunities to receive appropriate
care. This expansion of healthcare infrastructure is contributing to the broader
penetration of the acromegaly treatment market.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Acromegaly Treatment Market”
The Global Acromegaly Treatment Market is segmented into
drugs, route of administration, distribution channel, regional distribution,
company and region
Among drugs, growth hormone receptor antagonists (GHRAs) are the fastest-growing segment in the acromegaly treatment market, owing to their targeted mechanism of action: they directly block growth hormone receptors, thereby normalizing insulin-like growth factor 1 (IGF-1) levels. Unlike
somatostatin analogs, which reduce growth hormone secretion, GHRAs work
independently of tumor activity, making them effective for patients who do not
respond well to other treatments. The increasing prevalence of acromegaly, demand
for advanced therapies, and ongoing research and development efforts to improve
efficacy and administration drive their growth. Expanding clinical trials and
regulatory approvals further enhance their adoption in treatment protocols.
Based on the route of administration, the oral segment is
experiencing the fastest growth. This surge is primarily attributable to the introduction of new oral therapies that offer greater convenience and improved patient adherence compared with traditional injectable treatments. For instance, the
approval of Mycapssa, an oral formulation of octreotide, provides a noninvasive alternative to injections, thereby significantly improving patients' quality of life. Ongoing research and development efforts are focused on
expanding the availability of oral medications, further driving this segment's
growth. The preference for less invasive treatment options aligns with the
broader trend in healthcare toward patient-centered solutions, contributing to the rapid adoption and expansion of oral therapies in the management of acromegaly.
Based on region, Asia Pacific region is witnessing rapid
growth in the acromegaly treatment market due to several key factors. The
region has a substantial patient population, resulting in increased demand for
effective treatments. Additionally, advances in healthcare infrastructure and
rising healthcare expenditures have improved access to diagnostic and
therapeutic services. The heightened awareness about acromegaly and its
management has led to earlier diagnoses and interventions. The introduction and
adoption of novel therapies, including targeted drug classes, have expanded
treatment options. However, these factors contribute to the rapid growth of the acromegaly treatment market in the Asia-Pacific region.
Major companies operating in Global Acromegaly
Treatment Market are:
- Recordati S.p.A.
- Pfizer Inc.
- Validus Pharmaceuticals LLC
- Ipsen S.A.
- Crinetics Pharmaceuticals, Inc.
- Amryt Pharma plc
- Debiopharm International SA
- ADVANZ PHARMA CORP.
- Novartis Pharmaceuticals Corporation
- Amolyt Pharma SAS
Download Free Sample Report
Customers can also request for 10% free customization on
this report
“The Global Acromegaly Treatment Market is poised for
significant growth in the coming years, driven by a combination of factors.
Advancements in therapeutic approaches, including the development of novel
medications and treatment modalities, provide more effective options for
managing acromegaly. The rising incidence of acromegaly, attributed to improved
diagnostic capabilities and heightened awareness, is expanding the patient pool
in need of treatment. The continuous development of healthcare infrastructure,
particularly in emerging economies, is improving patient access to diagnosis
and management, fostering market expansion. The collaborative research efforts
and the pursuit of personalized treatment plans are further enhancing the
efficacy of acromegaly management”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.
“Acromegaly Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs (Somatostatin Analogs, Growth Hormone Receptor Antagonists, Dopamine Agonists, Combination Therapy), By Route of administration (Oral, Subcutaneous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region and Competition, 2021-2031F”, has evaluated the future
growth potential of Global Acromegaly Treatment Market and provides statistics
& information on market size, structure and future market growth. The report aims to provide cutting-edge market intelligence and help decision-makers make sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Acromegaly Treatment Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com